George Parise, CFO of Princeton BioPharma LLC, Barry Lederman, CFO of Halo Pharma, Andrew Einhorn, CFO of Edge Therapeutics, Jim Mastakas, SVP & CFO of Amneal Pharmaceuticals, and Brian Zietsman, President & CFO of Enteris BioPharma will be presenting Bio-tech and Pharma discussion, moderated by Mark Giamo, New Jersey Office Managing Partner, BDO, at 3:15 P.M., May 5th, MetLife Stadium, East Rutherford, NJ.CFOs and senior finance executives may attend at no cost, and non-CFOs may purchase tickets, by registering at www.CFOstudio.com.

Mark Giamo, New Jersey Office Managing Partner, BDO

In his role as New Jersey Office Managing Partner for BDO USA, LLP, Mark is responsible for managing all aspects of the assurance practice for BDO’s New Jersey Office. Mark also co-leads the NY Metro Technology Practice. Mark joined BDO in 1997 and has serviced publicly-traded, private, multi-national, private equity sponsored and growth-oriented companies in the technology industry. Mark spends a significant amount of time servicing SEC registrants as both the engagement partner and technical partner reviewer. In addition, Mark acts as an instructor for continuing education and plays an active role in the firm’s internal quality inspection program.

 Some of Mark’s professional affiliations include American Institute of Certified Public Accountants (AICPA), New Jersey State Society of Certified Public Accountants, Board of Directors, Special Olympics of New Jersey, and the Board of Directors, New Jersey Technology Council.

 Mark received a B.S. in Accounting from Villanova University.

Barry Lederman, Chief Financial Officer, Halo Pharma

Barry Lederman has extensive financial and international pharmaceutical experience, having led teams of several public and private companies with global operations. Prior to joining Halo, he served as the Vice President and CFO for Eisai Inc. with operations in the Americas Region, the CFO at Wedgewood Pharmacy, Nycomed US Inc., and Qualitrol Company LLC (a subsidiary of Danaher Corporation). He also spent 10 years with Roche in positions of increasing responsibility within Finance, culminating in his appointment as Senior Vice President – Head of Business Analysis and Controlling at Roche Centralized Diagnostics, headquartered in Mannheim, Germany. He is a CPA licensed in New Jersey and New York and gained his accounting experience at PwC.

Andrew Einhorn, Chief Financial Officer, Edge Therapeutics

Andrew Einhorn is the Chief Financial Officer of Edge Therapeutics, Inc. Previously, he served as the Executive Vice President, Corporate Development of the company. Mr. Einhorn has more than 10 years of experience in the pharmaceutical industry developing and executing corporate strategy. He also has more than 20 years of experience as an investment banker working extensively in corporate finance, capital markets and financial analysis. His experience includes numerous acquisition and licensing transactions across a variety of therapeutic areas and geographies.

 Prior to joining Edge Therapeutics, Mr. Einhorn was an independent consultant, served as CFO at Myos Corporation and was the Executive Vice President and Chief Financial Officer at Oceana Therapeutics, Inc.

 Mr. Einhorn was licensed as a Certified Public Accountant in New Jersey and a graduate of The American University where he completed a double major in Finance and Accounting.

Jim Mastakas, Senior Vice President and Chief Financial Officer, Amneal Pharmaceuticals

Jim oversees the global financial operations of the organization, including strategic planning, budgeting and forecasting, investment decisions, external financing, debt compliance, financial analysis and tax planning. In addition, he is responsible for the IT function. Jim has more than 18 years of experience in the pharmaceutical industry, including thirteen years in generics and specialty sectors. Prior to joining Amneal, Jim was chief financial officer at Sandoz NA, Eagle Pharmaceuticals and Corepharma, and vice president/controller for Mylan’s generic business. He also spent five years at Wyeth leading their External Reporting team. Jim holds a bachelor’s degree in accountancy from Bentley University and is a certified public accountant.

Brian Zietsman, President & Chief Financial Officer, Enteris BioPharma

Mr. Brian Zietsman, President and Chief Financial Officer, joined the Company in July 2013. He brings more than 20 years of strategic finance and accounting experience to his position, over half of which has been in the pharmaceutical industry for both public and private companies.

Prior to joining Enteris BioPharma, Mr. Zietsman was the Chief Financial Officer of Unigene Laboratories, Inc. where he played a pivotal role in that company’s restructuring. Prior to working at Unigene, he was the Corporate Controller at Duff & Phelps (NYSE DUF) and between 2005 and 2011, he worked in various financial capacities at Enzon Pharmaceuticals, Inc., (NASDAQ – ENZN), including Vice President and Corporate Controller. Prior to Enzon, Mr. Zietsman was the Corporate Controller at Reliant Pharmaceuticals, Inc., a privately held company which was acquired by GlaxoSmithKline, and earlier worked at Deloitte where he held various positions of increasing responsibility, leaving as a Senior Manager in the audit group.

Mr. Zietsman is a graduate from Rhodes University, South Africa where he earned his B. Com (Accounting), BSc (Computer Science) and HDIPACC certifications. Mr. Zietsman is a registered CPA.